V. Ellen Maher

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

V. Ellen Maher, Laura L. Fernandes, Chana Weinstock et al. · Journal of Clinical Oncology · 2019 · 346 citations

Medicine, Oncology, Pharmacology +17

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy

Daniel L. Suzman, Sundeep Agrawal, Yang‐Min Ning et al. · The Oncologist · 2018 · 200 citations · Full text

Medicine, Oncology, Pharmacology +15

Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary

Paul G. Kluetz, William F. Pierce, V. Ellen Maher et al. · Clinical Cancer Research · 2013 · 170 citations

Medicine, Oncology, Pharmacotherapy +17

Immunization With Mutant<i>p53</i>- and<i>K-ras</i>–Derived Peptides in Cancer Patients: Immune Response and Clinical Outcome

David P. Carbone, I. Frank Ciernik, Michael J. Kelley et al. · Journal of Clinical Oncology · 2005 · 169 citations · Full text

Life Sciences, Immunology, Oncology +17

FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis

James Xu, V. Ellen Maher, Lijun Zhang et al. · The Oncologist · 2017 · 151 citations · Full text

Medicine, Oncology, Pharmacology +17